Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares Issued
Ratios

Summit Therapeutics (SMMT) Non-Current Receivables: 2021-2024

Historic Non-Current Receivables for Summit Therapeutics (SMMT) over the last 3 years, with Dec 2024 value amounting to $698,000.

  • Summit Therapeutics' Non-Current Receivables fell 27.22% to $698,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $698,000, marking a year-over-year decrease of 27.22%. This contributed to the annual value of $698,000 for FY2024, which is 27.22% down from last year.
  • Summit Therapeutics' Non-Current Receivables amounted to $698,000 in Q4 2024, which was up 49.46% from $467,000 recorded in Q3 2024.
  • Summit Therapeutics' 5-year Non-Current Receivables high stood at $11.3 million for Q3 2021, and its period low was $212,000 during Q1 2024.
  • Moreover, its 3-year median value for Non-Current Receivables was $698,000 (2024), whereas its average is $1.1 million.
  • Data for Summit Therapeutics' Non-Current Receivables shows a maximum YoY crashed of 77.92% (in 2023) over the last 5 years.
  • Over the past 4 years, Summit Therapeutics' Non-Current Receivables (Quarterly) stood at $11.3 million in 2021, then crashed by 70.82% to $3.3 million in 2022, then slumped by 77.37% to $959,000 in 2023, then fell by 27.22% to $698,000 in 2024.
  • Its Non-Current Receivables stands at $698,000 for Q4 2024, versus $467,000 for Q3 2024 and $364,000 for Q2 2024.